Merrill maintains ZymoGenetics at buy

ZymoGenetics Inc. was maintained at buy with a $25.50 price objective by Merrill Lynch analyst Hari Sambasivam after the company released third-quarter results broadly consistent with Merrill estimates. The company's loss per share of $0.33 matched Merrill estimates and Sambasivam upped the 2005 earnings-per-share estimate to $1.42 from $1.40 due to an updated share count. Additionally, ZymoGenetics was able to move its lead product, rhThrombin, into a phase-3 trial during the third quarter.

Shares of the Seattle-based biopharmaceutical company were up $0.74, or 4.33%, at $17.82 on volume of 118,825 shares versus the three-month running average of 275,618 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.